824 related articles for article (PubMed ID: 8923867)
1. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
[TBL] [Abstract][Full Text] [Related]
2. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
[TBL] [Abstract][Full Text] [Related]
3. Source localization of androgen excess in adolescent girls.
Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
[TBL] [Abstract][Full Text] [Related]
4. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
Arroyo A; Laughlin GA; Morales AJ; Yen SS
J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
[TBL] [Abstract][Full Text] [Related]
5. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
6. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome.
Piltonen T; Koivunen R; Perheentupa A; Morin-Papunen L; Ruokonen A; Tapanainen JS
J Clin Endocrinol Metab; 2004 Aug; 89(8):3769-75. PubMed ID: 15292303
[TBL] [Abstract][Full Text] [Related]
7. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
8. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Ghizzoni L; Virdis R; Vottero A; Cappa M; Street ME; Zampolli M; Ibañez L; Bernasconi S
J Clin Endocrinol Metab; 1996 Feb; 81(2):601-6. PubMed ID: 8636275
[TBL] [Abstract][Full Text] [Related]
9. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome.
McCartney CR; Bellows AB; Gingrich MB; Hu Y; Evans WS; Marshall JC; Veldhuis JD
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E902-8. PubMed ID: 14736706
[TBL] [Abstract][Full Text] [Related]
10. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
11. Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study.
Petermann TS; Cartes A; Maliqueo M; Vantman D; Gutiérrez C; Toloza H; Echiburú B; Recabarren SE
Hum Reprod; 2004 Dec; 19(12):2742-7. PubMed ID: 15358722
[TBL] [Abstract][Full Text] [Related]
12. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
13. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
14. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
Rosenfield RL; Barnes RB; Ehrmann DA
J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
[TBL] [Abstract][Full Text] [Related]
15. Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing.
Ibáñez L; Potau N; Zampolli M; Street ME; Carrascosa A
Fertil Steril; 1997 May; 67(5):849-55. PubMed ID: 9130889
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment.
Suikkari AM; MacLachlan V; Montalto J; Calderon I; Healy DL; McLachlan RI
Hum Reprod; 1995 Mar; 10(3):513-9. PubMed ID: 7782424
[TBL] [Abstract][Full Text] [Related]
17. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
19. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
[TBL] [Abstract][Full Text] [Related]
20. Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome.
Sahin Y; Ayata D; Keleştimur F
Eur J Endocrinol; 1997 Apr; 136(4):410-5. PubMed ID: 9150702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
